AstraZeneca Stomach Drugs Pose No Heart Risk, FDA Finds
Posted on: Thursday, 9 August 2007, 15:02 CDT
The FDA has found no evidence pointing to a link between AstraZeneca's top-selling gastrointestinal drugs Nexium and Prilosec and increased risk of heart problems.
US regulators reviewed the drugs after two clinical trials suggested that they increased the risk of heart attacks and cardiac death.
Nexium and Prilosec are proton pump inhibitors used in the treatment of acid-reflux disease, ulcers and other conditions.
"Based on everything we know now, FDA's preliminary conclusion is that the observed difference in risk of heart attacks and other heart related problems seen in early analyses of the two small long-term studies is not a true effect," the regulator said in a statement.
Source: Datamonitor
Related Articles
- Never Too Early to Lower Heart Risk Factors
- Hormone Heart Risks Overstated for Some
- FDA, Duke to Probe Drugs' Heart Risk
- Glaxo adds strong heart risk warning to ADHD drug
- Glaxo adds heart risk warning to ADHD drug
- Doctors Debate Ritalin Warning; FDA Panel Reports Some Heart Risks
- Merck Canceled Project to Study Heart Risks of Vioxx in 2002
- Fending Off Dementia; Controlling Heart Risk in Midlife May Delay Alzheimer's, Study Finds
- Managing Type II Diabetes Sharply Cuts Heart Risk
- Skimping on Sleep Raises Heart Risk for Women
 |
 |
User Comments (0)
RSS Feeds